Objective To evaluate the risk of reclassification on serial biopsy for Caucasian and African
American (AA) men with very low-risk (VLR) prostate cancer enrolled in a large prospective …

There is emerging evidence that microRNAs (miRNAs) dysregulation is involved in the
genesis and the progression of Prostate Cancer (PCa), thus potentially increasing their use …

Objective To test the expandability of active surveillance (AS) to Gleason score 3+ 4 cancers
by assessing the unfavorable disease risk in a large multi-institutional cohort. Materials and …

Background: Inaccurate risk classification and the burden of unnecessary biopsies are a
challenge due to the limited ability of current risk assessment tools and modalities to …

Purpose To assess the performance of prostate health index (PHI) and prostate cancer
antigen 3 (PCA3) when added to the PRIAS or Epstein criteria in predicting the presence of …

At present, prostate-specific antigen (PSA) is used as a clinical biomarker for prostate cancer
(PCa) diagnosis; however, a large number of patients with benign prostate hyperplasia …

The aims of this study were to investigate the immunohisto-chemical expression and
potential prognostic significance of putative cancer stems cell markers ALDH1, EZH2 and …

Purpose Gleason grading is the strongest predictor of prostate cancer outcome and
commonly used to decide for or against the different treatment options. However, Gleason …

Purpose We examined the frequency of followup prostate specific antigen testing and
prostate biopsy among men treated with active surveillance in the academic and community …

Active surveillance (AS) is currently a widely accepted treatment option for men with
clinically localized prostate cancer (PCa). Several reports have highlighted the association …